Insights Into Accenture (ACN) Q2: Wall Street Projections for Key Metrics

16.03.26 14:15 Uhr

Werte in diesem Artikel
Aktien

170,96 EUR 1,16 EUR 0,68%

40,00 EUR 0,00 EUR 0,00%

Indizes

3.210,0 PKT 0,4 PKT 0,01%

6.582,7 PKT 7,4 PKT 0,11%

The upcoming report from Accenture (ACN) is expected to reveal quarterly earnings of $2.87 per share, indicating an increase of 1.8% compared to the year-ago period. Analysts forecast revenues of $17.76 billion, representing an increase of 6.6% year over year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.Bearing this in mind, let's now explore the average estimates of specific Accenture metrics that are commonly monitored and projected by Wall Street analysts.The combined assessment of analysts suggests that 'Revenues- Type of Work- Consulting' will likely reach $8.73 billion. The estimate indicates a change of +5.4% from the prior-year quarter.Analysts forecast 'Revenues- Type of Work- Managed Services' to reach $9.06 billion. The estimate points to a change of +8.2% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Revenues- Industry Groups- Product' of $5.37 billion. The estimate indicates a year-over-year change of +6.4%.According to the collective judgment of analysts, 'Revenues- Industry Groups- Health & Public Service' should come in at $3.76 billion. The estimate indicates a change of +4.2% from the prior-year quarter.The average prediction of analysts places 'Revenues- Industry Groups- Financial services' at $3.25 billion. The estimate suggests a change of +7.9% year over year.It is projected by analysts that the 'Revenues- Industry Groups- Communications, Media & Technology' will reach $2.91 billion. The estimate indicates a year-over-year change of +6.7%.Analysts expect 'Geographic Revenue- Americas' to come in at $9.14 billion. The estimate indicates a year-over-year change of +6.9%.The consensus estimate for 'Geographic Revenue- Asia Pacific' stands at $2.20 billion. The estimate indicates a year-over-year change of -4.3%.Analysts predict that the 'Geographic Revenue- EMEA' will reach $6.34 billion. The estimate suggests a change of +9.3% year over year.The consensus among analysts is that 'New Bookings - Total' will reach $21.68 billion. The estimate is in contrast to the year-ago figure of $20.91 billion.Based on the collective assessment of analysts, 'New Bookings - Managed Services' should arrive at $11.24 billion. The estimate compares to the year-ago value of $10.44 billion.Analysts' assessment points toward 'New Bookings - Consulting' reaching $10.44 billion. The estimate is in contrast to the year-ago figure of $10.47 billion. View all Key Company Metrics for Accenture here>>> Accenture shares have witnessed a change of -12.3% in the past month, in contrast to the Zacks S&P 500 composite's -2.9% move. With a Zacks Rank #3 (Hold), ACN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accenture PLC (ACN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Q2 und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: Zacks

Nachrichten zu Accenture plc

Analysen zu Accenture plc

DatumRatingAnalyst
20.09.2018Accenture BuyDeutsche Bank AG
20.03.2018Accenture OutperformWedbush Morgan Securities Inc.
22.12.2017Accenture BuyPivotal Research Group
22.12.2017Accenture Equal WeightBarclays Capital
22.12.2017Accenture OverweightCantor Fitzgerald
DatumRatingAnalyst
20.09.2018Accenture BuyDeutsche Bank AG
20.03.2018Accenture OutperformWedbush Morgan Securities Inc.
22.12.2017Accenture BuyPivotal Research Group
22.12.2017Accenture OverweightCantor Fitzgerald
08.11.2017Accenture BuyPivotal Research Group
DatumRatingAnalyst
22.12.2017Accenture Equal WeightBarclays Capital
27.09.2017Accenture Equal WeightBarclays Capital
22.12.2016Accenture Equal WeightBarclays Capital
30.09.2016Accenture Equal WeightBarclays Capital
28.03.2016Accenture NeutralUBS AG
DatumRatingAnalyst
19.12.2011Accenture sellSociété Générale Group S.A. (SG)
01.10.2010Accenture sellKaufman Bros., LP
26.08.2010Accenture sellKaufman Bros., LP
26.09.2006Update Accenture Ltd. : UnderperformRBC Capital Markets

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Accenture plc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen